Clinical Trials
83 trialsNCT07509034 2026-05-27
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
National Institutes of Health Clinical Center (CC)
Phase 1 Not yet recruiting
NCT07524530 2026-05-27
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Not yet recruiting
NCT07572136 2026-05-27
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
National Institutes of Health Clinical Center (CC)
Phase 1 Not yet recruiting
NCT07593482 2026-05-18
FC-BALANCE
Swiss Cancer Institute
Phase 2 Not yet recruiting
NCT07588698 2026-05-15
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
University of California, San Francisco
Phase 2 Not yet recruiting
NCT07444710 2026-05-13
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT07583303 2026-05-13
BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation
City of Hope Medical Center
Phase 1 Not yet recruiting
NCT07193420 2026-05-12
REDUCy
Assistance Publique - Hôpitaux de Paris
Phase 3 Not yet recruiting
NCT07297667 2026-05-12
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Canadian Cancer Trials Group
Phase 1 Not yet recruiting
NCT07444632 2026-05-08
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07300475 2026-05-07
Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients
Washington University School of Medicine
Phase 1 Not yet recruiting
NCT07164469 2026-05-06
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07569965 2026-05-06
FRONTIER
Miltenyi Biomedicine GmbH
Phase 2 Not yet recruiting
NCT07509008 2026-05-05
Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum
M.D. Anderson Cancer Center
Phase 1/2 Not yet recruiting
NCT07564232 2026-05-04
Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07565324 2026-05-04
UC HER
National Taiwan University Hospital
Phase 2 Not yet recruiting
NCT06594939 2026-05-01
Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
Medical College of Wisconsin
Phase 2 Not yet recruiting
NCT07548983 2026-04-23
Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
OHSU Knight Cancer Institute
Phase 1 Not yet recruiting
NCT07535710 2026-04-17
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
Shanghai Jiao Tong University School of Medicine
Phase 1/2 Not yet recruiting
NCT07535762 2026-04-17
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
Shanghai Jiao Tong University School of Medicine
Phase 2 Not yet recruiting
NCT07349771 2026-04-16
Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial
Mayo Clinic
Phase 2 Not yet recruiting
NCT07361133 2026-04-16
Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer
National Cancer Institute, Egypt
Phase 2 Not yet recruiting
NCT07437963 2026-04-15
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
NCT07519187 2026-04-09
CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms
The General Hospital of Western Theater Command
Phase EARLY_PHASE1 Not yet recruiting
NCT06986434 2026-04-08
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
Affiliated Hospital to Academy of Military Medical Sciences
Phase EARLY_PHASE1 Not yet recruiting
NCT07432178 2026-04-02
CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）
Fudan University
Phase 3 Not yet recruiting
NCT07224672 2026-03-17
ALANIS
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT04579523 2026-03-13
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1 Not yet recruiting
NCT07466316 2026-03-12
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Children's Oncology Group
Phase 3 Not yet recruiting
NCT07463313 2026-03-11
6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2/3 Not yet recruiting
NCT07137481 2026-03-04
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT05565105 2026-03-03
CD34+ Transplants for Leukemia and Lymphoma
Baptist Health South Florida
Phase 2 Not yet recruiting
NCT07416682 2026-02-25
CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms
Affiliated Hospital to Academy of Military Medical Sciences
Phase EARLY_PHASE1 Not yet recruiting
NCT07423611 2026-02-20
RACE
Fudan University
Phase 2 Not yet recruiting
NCT07390539 2026-02-05
B7-H3.CD28Z.CART in CNS Neoplasms
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07367685 2026-01-26
Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma
The Second Affiliated Hospital of Fujian Medical University
Phase 1 Not yet recruiting
NCT07358260 2026-01-22
B7-H3.CD28Z.CART in Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07342738 2026-01-15
TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
Sun Yat-sen University
Phase EARLY_PHASE1 Not yet recruiting
NCT07341867 2026-01-14
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07072585 2025-12-31
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
Children's Oncology Group
Phase 2/3 Not yet recruiting
NCT07301138 2025-12-24
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
Ruijin Hospital
Phase 2 Not yet recruiting
NCT07297914 2025-12-22
FORUM2
Bambino Gesù Hospital and Research Institute
Phase 2/3 Not yet recruiting
NCT07278856 2025-12-12
Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
City of Hope Medical Center
Phase 1 Not yet recruiting
NCT07231250 2025-11-19
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07227584 2025-11-12
ALL Backbone in AYAs
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
NCT07225439 2025-11-06
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Case Comprehensive Cancer Center
Phase 1 Not yet recruiting
NCT07199413 2025-09-30
Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT07157514 2025-09-10
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
Actinium Pharmaceuticals
Phase 2/3 Not yet recruiting
NCT07144657 2025-08-27
GastricMALToma
National Taiwan University Hospital
Phase 2 Not yet recruiting
NCT07035379 2025-08-22
A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL
Zhejiang Teruisi Pharmaceutical Inc.
Phase 1/2 Not yet recruiting